Join us on Thursday, 5 December 2024 from 7:00 pm to 8:00 pm (AEDT) as we discuss the latest trials on the management of MASH in people with and without diabetes. We’ll focus on the Australian clinical context, considering GESA’s recent position statement on MAFLD screening and diagnosis as well as ADS’ provision statement on managing the condition.

This webinar will cover:

• Epidemiology and diagnosis of MAFLD and MASH
• Key clinical studies and outcomes
• Australian position statements/guidelines
• Implications for the clinical management of MASH

Speakers

Click here to view the event flyer.
Click here to register for the webinar.

Registration is free to attend.

For any further information please contact the ADS Secretariat via email to ads@diabetessociety.com.au